Antifertility activity of systemically administered proteinase (acrosin) inhibitors.
Low molecular weight, synthetic proteinase inhibitors that inhibit sperm-associated acrosin, were released systemically in female mice at a constant rate from minipumps. The release was timed so that, after mating, the minipumps were depleted of inhibitor before blastocyst implantation took place. Three of the inhibitors: 4-aminobenzamidine (ABD), 4-nitrophenyl-4-guanidino-benzoate (NPGB) and 4-methylumbelliferone-4-guanidinobenzoate (MUGB) caused a 50% decrease in fertility, the last two at very low concentrations. The fourth inhibitor, benzamidine (BD), which is also the weakest inhibitor of mouse acrosin and in vitro fertilization, had no effect. These results show that at least one of the processes leading to fertilization or early blastogenesis, is dependent on proteolytic activity and that the systemic application of proteinase inhibitors inhibits conception. MUGB possessed low toxicity and a high margin of safety, encouraging the development of phenol derivatives of guanidinobenzoic acid as contraceptive agents.
D000176:Acrosin / Q000037:antagonists & inhibitors*; D000578:Amidines / Q000494:pharmacology*; D000818:Animals; D001550:Benzamidines / Q000494:pharmacology*; D001565:Benzoates / Q000494:pharmacology*; D003271:Contraceptive Agents, Female / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D004343:Drug Implants; D005260:Female; D006923:Hymecromone / Q000031:analogs & derivatives / Q000494:pharmacology* / Q000633:toxicity; D051379:Mice; D011480:Protease Inhibitors; D014468:Umbelliferones / Q000494:pharmacology*
C017532:4-methylumbelliferylguanidinobenzoate; D000578:Amidines; D001550:Benzamidines; D001565:Benzoates; D003271:Contraceptive Agents, Female; D004343:Drug Implants; D011480:Protease Inhibitors; D014468:Umbelliferones; C002238:4-nitrophenyl 4'-guanidinobenzoate; D006923:Hymecromone; C006500:4-aminobenzamidine; D000176:Acrosin